Terms: = Ovarian cancer AND PLCG1, PLC1, 5335, ENSG00000124181, PLC-II, Plcg1, PLCgamma1, PLC148
7 results:
1. 8-Br-cGMP suppresses tumor progression through EGFR/PLC γ1 pathway in epithelial ovarian cancer.
Wu M; Mu C; Yang H; Wang Y; Ma P; Li S; Wang Z; Lan T
Mol Biol Rep; 2024 Jan; 51(1):140. PubMed ID: 38236447
[TBL] [Abstract] [Full Text] [Related]
2. BDNF activates TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis.
Xu Y; Jiang WG; Wang HC; Martin T; Zeng YX; Zhang J; Qi YS
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5093-5100. PubMed ID: 31298409
[TBL] [Abstract] [Full Text] [Related]
3. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB
Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810
[TBL] [Abstract] [Full Text] [Related]
4. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract] [Full Text] [Related]
5. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
Timsah Z; Ahmed Z; Ivan C; Berrout J; Gagea M; Zhou Y; Pena GN; Hu X; Vallien C; Kingsley CV; Lu Y; Hancock JF; Liu J; Gladden AB; Mills GB; Lopez-Berestein G; Hung MC; Sood AK; Bogdanov M; Ladbury JE
Oncogene; 2016 Apr; 35(17):2186-96. PubMed ID: 26212011
[TBL] [Abstract] [Full Text] [Related]
6. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
Block MS; Charbonneau B; Vierkant RA; Fogarty Z; Bamlet WR; Pharoah PD; ; ; ; Rossing MA; Cramer D; Pearce CL; Schildkraut J; Menon U; Kjaer SK; Levine DA; Gronwald J; Culver HA; Whittemore AS; Karlan BY; Lambrechts D; Wentzensen N; Kupryjanczyk J; Chang-Claude J; Bandera EV; Hogdall E; Heitz F; Kaye SB; Fasching PA; Campbell I; Goodman MT; Pejovic T; Bean YT; Hays LE; Lurie G; Eccles D; Hein A; Beckmann MW; Ekici AB; Paul J; Brown R; Flanagan JM; Harter P; du Bois A; Schwaab I; Hogdall CK; Lundvall L; Olson SH; Orlow I; Paddock LE; Rudolph A; Eilber U; Dansonka-Mieszkowska A; Rzepecka IK; Ziolkowska-Seta I; Brinton LA; Yang H; Garcia-Closas M; Despierre E; Lambrechts S; Vergote I; Walsh CS; Lester J; Sieh W; McGuire V; Rothstein JH; Ziogas A; Lubiński J; Cybulski C; Menkiszak J; Jensen A; Gayther SA; Ramus SJ; Gentry-Maharaj A; Berchuck A; Wu AH; Pike MC; Van Den Berg D; Terry KL; Vitonis AF; Ramirez SM; Rider DN; Knutson KL; Sellers TA; Phelan CM; Doherty JA; Johnatty SE; deFazio A; Song H; Tyrer J; Kalli KR; Fridley BL; Cunningham JM; Goode EL
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1421-7. PubMed ID: 24740199
[TBL] [Abstract] [Full Text] [Related]
7. Effects of HER2-binding affibody molecules on intracellular signaling pathways.
Ekerljung L; Steffen AC; Carlsson J; Lennartsson J
Tumour Biol; 2006; 27(4):201-10. PubMed ID: 16651854
[TBL] [Abstract] [Full Text] [Related]
